Completed PHASE1 INTERVENTIONAL NCT00002373

The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients

A Phase I/II Trial to Evaluate the Tolerability, Anti-CMV Activity and Pharmacokinetics of 1263W94 Following Multiple Oral Administration of Escalating Doses in HIV-Infected Patients With Asymptomatic CMV Shedding

Sponsor: Glaxo Wellcome

Conditions Cytomegalovirus Infections HIV Infections

Interventions Maribavir

Updated 5 times since 2017 Last updated: Jun 23, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Cytomegalovirus Infections and HIV Infections and is currently completed. Glaxo Wellcome leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Glaxo Wellcome

Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Francisco, United States